A call for greater accountability in institutional decision-making processes that too often ignore realities and patient needs. Spending priorities delay and deny access to medicines. Term limits for advisory committees can lead to renewal and new ideas. They should be accompanied by independent oversight and transparency. We explore private markets and digital platforms as drivers of access and reform, while defending patients’ right to research treatments however they like.
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 6 November
November 6, 2026 - - Podcast -
Omico names laboratory partners to expand genomic profiling for Australians with cancer
November 6, 2026 - - Latest News -
Marie Guillet joins the European Australian Business Council board
November 6, 2026 - - Latest News -
The next agreements must end the culture of enforced silence
November 6, 2026 - - Latest News -
The lessons we can take from 'Robodebt' and the Reserve Bank reforms
November 6, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News
